These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 34772407)

  • 41. Effects of propofol-dexmedetomidine combination on ischemia reperfusion-induced cerebral injury.
    Wang Z; Kou D; Li Z; He Y; Yu W; Du H
    NeuroRehabilitation; 2014; 35(4):825-34. PubMed ID: 25323082
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dexmedetomidine Attenuates Myocardial Injury Induced by Renal Ischemia/Reperfusion by Inhibiting the HMGB1-TLR4-MyD88-NF-κB Signaling Pathway.
    Zhang B; Zhang J; Ainiwaer Y; He B; Geng Q; Lin L; Li X
    Ann Clin Lab Sci; 2021 May; 51(3):376-384. PubMed ID: 34162568
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dexmedetomidine attenuates renal fibrosis via α2-adrenergic receptor-dependent inhibition of cellular senescence after renal ischemia/reperfusion.
    Li Q; Chen C; Chen X; Han M; Li J
    Life Sci; 2018 Aug; 207():1-8. PubMed ID: 29729264
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dexmedetomidine protects against ischemia-reperfusion injury in rat skeletal muscle.
    Dong X; Xing Q; Li Y; Han X; Sun L
    J Surg Res; 2014 Jan; 186(1):240-5. PubMed ID: 24007817
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dexmedetomidine Ameliorates Post-CPB Lung Injury in Rats by Activating the PI3K/Akt Pathway.
    Li J; Dou X; Li D; He M; Han M; Zhang H
    J Invest Surg; 2020 Jul; 33(6):576-583. PubMed ID: 30913929
    [No Abstract]   [Full Text] [Related]  

  • 46. Ischaemic preconditioning and pharmacological preconditioning with dexmedetomidine in an equine model of small intestinal ischaemia-reperfusion.
    König KS; Verhaar N; Hopster K; Pfarrer C; Neudeck S; Rohn K; Kästner SBR
    PLoS One; 2020; 15(4):e0224720. PubMed ID: 32348301
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The α2AR/Caveolin-1/p38MAPK/NF-κB axis explains dexmedetomidine protection against lung injury following intestinal ischaemia-reperfusion.
    Xu L; Li T; Chen Q; Liu Z; Chen Y; Hu K; Zhang X
    J Cell Mol Med; 2021 Jun; 25(13):6361-72. PubMed ID: 34114328
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dexmedetomidine protects hepatic cells against oxygen-glucose deprivation/reperfusion injury via lncRNA CCAT1.
    Zhou Z; Chen Q; Wan L; Zheng D; Li Z; Wu Z
    Cell Biol Int; 2018 Sep; 42(9):1250-1258. PubMed ID: 29851220
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dexmedetomidine Preconditioning Protects Rats from Renal Ischemia-Reperfusion Injury Accompanied with Biphasic Changes of Nuclear Factor-Kappa B Signaling.
    Bao N; Tang B; Wang J
    J Immunol Res; 2020; 2020():3230490. PubMed ID: 32377532
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dexmedetomidine protects against renal ischemia and reperfusion injury by inhibiting the JAK/STAT signaling activation.
    Si Y; Bao H; Han L; Shi H; Zhang Y; Xu L; Liu C; Wang J; Yang X; Vohra A; Ma D
    J Transl Med; 2013 Jun; 11():141. PubMed ID: 23759023
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dexmedetomidine enables copper homeostasis in cerebral ischemia/reperfusion via ferredoxin 1.
    Guo Q; Ma M; Yu H; Han Y; Zhang D
    Ann Med; 2023 Dec; 55(1):2209735. PubMed ID: 37162502
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of dexmedetomidine on myocardial ischemia-reperfusion injury through PI3K-Akt-mTOR signaling pathway.
    Zhang J; Jiang H; Liu DH; Wang GN
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(15):6736-6743. PubMed ID: 31378917
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dexmedetomidine attenuates lung apoptosis induced by renal ischemia-reperfusion injury through α
    Li J; Chen Q; He X; Alam A; Ning J; Yi B; Lu K; Gu J
    J Transl Med; 2018 Mar; 16(1):78. PubMed ID: 29566706
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dexmedetomidine protects against cisplatin-induced acute kidney injury in mice through regulating apoptosis and inflammation.
    Liang H; Liu HZ; Wang HB; Zhong JY; Yang CX; Zhang B
    Inflamm Res; 2017 May; 66(5):399-411. PubMed ID: 28224201
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effects of dexmedetomidine on mesenteric arterial occlusion-associated gut ischemia and reperfusion-induced gut and kidney injury in rabbits.
    Kiliç K; Hanci V; Selek S; Sözmen M; Kiliç N; Citil M; Yurtlu DA; Yurtlu BS
    J Surg Res; 2012 Nov; 178(1):223-32. PubMed ID: 22560540
    [TBL] [Abstract][Full Text] [Related]  

  • 56. DEXMEDETOMIDINE PREVENTS PDIA3 DECREASE BY ACTIVATING α2-ADRENERGIC RECEPTOR TO ALLEVIATE INTESTINAL I/R IN MICE.
    Zhan Y; Chen Z; Qiu Y; Deng Q; Huang W; Wen S; Shen J
    Shock; 2022 Dec; 58(6):556-564. PubMed ID: 36374735
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The cardioprotective effect of dexmedetomidine on regional ischemia/reperfusion injury in type 2 diabetic rat hearts.
    Deng L; Chen H; Wei N; Zhang Z; Wang G
    Microvasc Res; 2019 May; 123():1-6. PubMed ID: 30179598
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dexmedetomidine protects against apoptosis induced by hypoxia/reoxygenation through the inhibition of gap junctions in NRK-52E cells.
    Luo C; Yuan D; Yao W; Cai J; Zhou S; Zhang Y; Hei Z
    Life Sci; 2015 Feb; 122():72-7. PubMed ID: 25529146
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Effect of dexmedetomidine on renal injury induced by lung ischemia/reperfusion in mice].
    Xiang BQ; Gao H; Luo ZY; Fang ZX; Wang WT
    Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2017 Apr; 33(4):380-384. PubMed ID: 29926648
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dexmedetomidine alleviates pulmonary ischemia-reperfusion injury through modulating the miR-21-5p/Nr4a1 signaling pathway.
    Dong W; Yang H; Cheng M; Zhang X; Yin J; Zeng Z; Huang G
    Acta Biochim Pol; 2020 Dec; 67(4):521-529. PubMed ID: 33332077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.